US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 1.130
- -0.090-7.38%
Close Oct 11 16:00 ET
22.38MMarket Cap-1738P/E (TTM)
1.240High1.090Low263.29KVolume1.220Open1.220Pre Close302.45KTurnover1.77%Turnover RatioLossP/E (Static)19.81MShares2.33052wk High-13.14P/B16.79MFloat Cap0.40052wk Low--Dividend TTM14.86MShs Float8.180Historical High--Div YieldTTM12.30%Amplitude0.400Historical Low1.148Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
NeuroSense Therapeutics Stock Forum
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NeuroSense Therapeutics (NASDAQ: NRSN) has initiated the regulatory process for early commercialization approval of PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This decision follows positive Phase 2b trial results showing PrimeC reduces ALS disease progression by 36% (p=0.009) and improves survival rates by 4...
Neurosense Therapeutics Granted Key U.S. Patent for Novel Primec Formulation, Its Lead Asset for ALS and Alzheimer's
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, mile...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company known for developing novel treatments for severe neurodegenerative diseases, has recently announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM). This study evaluated both the safety and efficac...
Neurosense Therapeutics Announces Positive Biomarker Data From ALS Phase 2B Clinical Trial
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients, showing a significant improvement in complication-free survival. Specifically, the study demonstrated a 57% difference in favor of PrimeC over placebo in the ITT population, and a 73% difference in the PP population. ...
No comment yet